FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2019929008> ?p ?o ?g. }

• W2019929008 endingPage "216" @default.
• W2019929008 startingPage "206" @default.
• W2019929008 abstract "Background: A controlled-release (CR) formulation of simvastatin was recently developed in Korea. The formulation is expected to yield a lower Cmax and similar AUC values compared with the immediate-release (IR) formulation. Objective: The goal of this study was to compare the pharmacokinetics of the new CR formulation and an IR formulation of simvastatin after single- and multiple-dose administration in healthy Korean subjects. This study was developed as part of a product development project at the request of the Korean regulatory agency. Methods: This was a randomized, open-label, parallelgroup, 2-part study. Eligible subjects were healthy male or female volunteers between the ages of 19 and 55 years and within 20% of their ideal weight. In part I, each subject received a single dose of the CR or IR formulation of simvastatin 40 mg orally (20 mg × 2 tablets) after fasting. In part II, each subject received the same dose of the CR or IR formulation for 8 consecutive days. Blood samples were obtained for 48 hours after the dose in part I and after the first and the last dose in part II. Pharmacokinetic parameters were determined for both simvastatin (the inactive prodrug) and simvastatin acid (the active moiety). An adverse event (AE) was defined as any unfavorable sign (including an abnormal laboratory finding) or symptom, regardless of whether it had a causal relationship with the study medication. Serious AEs were defined as any events that are considered life threatening, require hospitalization or prolongation of existing hospitalization, cause persistent or significant disability or incapacity, or result in congenital abnormality, birth defect, or death. AEs were determined based on patient interviews and physical examinations. Results: Twenty-four healthy subjects (17 men, 7 women; mean [SD] age, 29 [7] years; age range, 22–50 years) were enrolled in part I, and 29 subjects (17 men, 12 women; mean age, 33 [9] years; age range, 19–55 years) were enrolled in part II. For simvastatin acid, Cmax was significantly smaller (1.68 vs 3.62 ng/mL; P < 0.013) and Tmax and apparent t½ significantly longer (10.33 vs 4.04 hours [P < 0.001] and 11.41 vs 4.16 hours [P < 0.011]) for the CR formulation compared with the IR formulation, respectively, after the single-dose administration. After the multiple-dose administration, for simvastatin acid, the Cmax for the CR formulation was significantly smaller (3.40 vs 5.16 ng/mL; P < 0.037), while the values for Tmax and apparent t½ were significantly longer (8.40 vs 4.57 hours and 13.09 vs 4.52 hours; both, P < 0.001) compared with the IR formulation. There was no significant difference between the CR and the IR formulations for AUC0−last and AUC0−∞) during either the single- or multiple-dose testing. Both CR and IR formulations were well tolerated in all subjects, and no serious AEs or adverse drug reactions were found. No subjects reported any AEs during part I of the study. During part II, 6 subjects (3 from each formulation group) reported headache, 1 reported lumbago before the dose, and 1 subject had a hordeolum while receiving the CR formulation. Conclusions: The Cmax of the simvastatin CR formulation was found to be significantly smaller while the AUC of the active moiety did not differ significantly from that of the IR formulation in these healthy Korean subjects. The simvastatin CR and IR formulations were well tolerated, with no serious AEs observed. To evaluate the characteristics of the CR formulation, its clinical efficacy must be examined in patient populations." @default.
• W2019929008 created "2016-06-24" @default.
• W2019929008 creator A5014783730 @default.
• W2019929008 creator A5017519850 @default.
• W2019929008 creator A5021066621 @default.
• W2019929008 creator A5050832567 @default.
• W2019929008 creator A5054399150 @default.
• W2019929008 creator A5068391399 @default.
• W2019929008 creator A5073604371 @default.
• W2019929008 creator A5074131016 @default.
• W2019929008 creator A5075482380 @default.
• W2019929008 creator A5089840714 @default.
• W2019929008 date "2010-01-01" @default.
• W2019929008 modified "2023-10-12" @default.
• W2019929008 title "Pharmacokinetic comparison of controlled-release and immediate-release oral formulations of simvastatin in healthy Korean subjects: A randomized, open-label, parallel-group, single- and multiple-dose study" @default.
• W2019929008 cites W158929996 @default.
• W2019929008 cites W1965783053 @default.
• W2019929008 cites W1979919506 @default.
• W2019929008 cites W1987049947 @default.
• W2019929008 cites W1990043687 @default.
• W2019929008 cites W2004668949 @default.
• W2019929008 cites W2005776262 @default.
• W2019929008 cites W2054377125 @default.
• W2019929008 cites W2059981792 @default.
• W2019929008 cites W2066398399 @default.
• W2019929008 cites W2069240671 @default.
• W2019929008 cites W2081571706 @default.
• W2019929008 cites W2093695459 @default.
• W2019929008 cites W2108799014 @default.
• W2019929008 cites W2118342649 @default.
• W2019929008 cites W2120052409 @default.
• W2019929008 cites W2122009278 @default.
• W2019929008 cites W2122099263 @default.
• W2019929008 cites W2125149319 @default.
• W2019929008 cites W2147153780 @default.
• W2019929008 cites W2155598961 @default.
• W2019929008 cites W2322095705 @default.
• W2019929008 cites W2403066849 @default.
• W2019929008 cites W3214803073 @default.
• W2019929008 cites W4243501503 @default.
• W2019929008 cites W4297821733 @default.
• W2019929008 doi "https://doi.org/10.1016/j.clinthera.2010.01.026" @default.
• W2019929008 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20171425" @default.
• W2019929008 hasPublicationYear "2010" @default.
• W2019929008 type Work @default.
• W2019929008 sameAs 2019929008 @default.
• W2019929008 citedByCount "18" @default.
• W2019929008 countsByYear W20199290082012 @default.
• W2019929008 countsByYear W20199290082013 @default.
• W2019929008 countsByYear W20199290082014 @default.
• W2019929008 countsByYear W20199290082015 @default.
• W2019929008 countsByYear W20199290082017 @default.
• W2019929008 countsByYear W20199290082018 @default.
• W2019929008 countsByYear W20199290082020 @default.
• W2019929008 countsByYear W20199290082022 @default.
• W2019929008 countsByYear W20199290082023 @default.
• W2019929008 crossrefType "journal-article" @default.
• W2019929008 hasAuthorship W2019929008A5014783730 @default.
• W2019929008 hasAuthorship W2019929008A5017519850 @default.
• W2019929008 hasAuthorship W2019929008A5021066621 @default.
• W2019929008 hasAuthorship W2019929008A5050832567 @default.
• W2019929008 hasAuthorship W2019929008A5054399150 @default.
• W2019929008 hasAuthorship W2019929008A5068391399 @default.
• W2019929008 hasAuthorship W2019929008A5073604371 @default.
• W2019929008 hasAuthorship W2019929008A5074131016 @default.
• W2019929008 hasAuthorship W2019929008A5075482380 @default.
• W2019929008 hasAuthorship W2019929008A5089840714 @default.
• W2019929008 hasConcept C108215921 @default.
• W2019929008 hasConcept C112705442 @default.
• W2019929008 hasConcept C126322002 @default.
• W2019929008 hasConcept C168563851 @default.
• W2019929008 hasConcept C197934379 @default.
• W2019929008 hasConcept C22979827 @default.
• W2019929008 hasConcept C2776329913 @default.
• W2019929008 hasConcept C2777056448 @default.
• W2019929008 hasConcept C71924100 @default.
• W2019929008 hasConcept C98274493 @default.
• W2019929008 hasConceptScore W2019929008C108215921 @default.
• W2019929008 hasConceptScore W2019929008C112705442 @default.
• W2019929008 hasConceptScore W2019929008C126322002 @default.
• W2019929008 hasConceptScore W2019929008C168563851 @default.
• W2019929008 hasConceptScore W2019929008C197934379 @default.
• W2019929008 hasConceptScore W2019929008C22979827 @default.
• W2019929008 hasConceptScore W2019929008C2776329913 @default.
• W2019929008 hasConceptScore W2019929008C2777056448 @default.
• W2019929008 hasConceptScore W2019929008C71924100 @default.
• W2019929008 hasConceptScore W2019929008C98274493 @default.
• W2019929008 hasIssue "1" @default.
• W2019929008 hasLocation W20199290081 @default.
• W2019929008 hasLocation W20199290082 @default.
• W2019929008 hasOpenAccess W2019929008 @default.
• W2019929008 hasPrimaryLocation W20199290081 @default.
• W2019929008 hasRelatedWork W1978721469 @default.
• W2019929008 hasRelatedWork W1991965294 @default.
• W2019929008 hasRelatedWork W2348752634 @default.
• W2019929008 hasRelatedWork W2355979670 @default.
• W2019929008 hasRelatedWork W2360876458 @default.
• W2019929008 hasRelatedWork W2371426955 @default.

• next